These include loss of Ch.1p, amplification of Ch.1q, PDGFRA, and CDK4, copy-number losses in tumor suppressors such as CDKN2A and BCOR, and pathogenic mutations in TP53, NF1, and MET (fusion events). This evidence concerns the gene PDGFRA and neoplasm.